Document:

Summary Term Sheet for Standby Commitment dated September 22, 2009

 Exhibit 10.37 
 $3,000,000 STANDBY COMMITMENT 
 SUMMARY OF TERMS AND
CONDITIONS 
 This Summary of Terms and Conditions of a $3,000,000 Standby Commitment (the “Standby Commitment Term Sheet”) is
for convenience of reference only and shall not be considered to be exhaustive as to the final terms and conditions that shall govern the financing arrangements between the parties. In the event of a conflict between the provisions of this Standby
Commitment Term Sheet and any relevant definitive agreement, the latter shall prevail. This Standby Commitment Term Sheet and all matters related hereto are confidential, and the parties agree to maintain the confidentiality of this Standby
Commitment Term Sheet and the related matters unless written authorization to the contrary is provided in advance of any non-authorized disclosure or unless disclosure is otherwise required by applicable law. The parties agree that each of them may
disclose this Standby Commitment Term Sheet and the related matters to his or its respective financial and legal advisors. All amounts in this Standby Commitment Term Sheet are expressed in U.S. dollars. 
  

							
	Background and Objective:	  	This Standby Commitment Term Sheet is executed and delivered between Authentidate Holding Corp. (“Authentidate”) and the purchasers as identified
below (the “Purchasers”) to set forth the terms and conditions governing a financing arrangement between the parties hereto. To assure adequate funds available for Authentidate’s general corporate purposes, the Purchasers have
agreed to provide Authentidate with a standby commitment to purchase senior secured convertible debentures of Authentidate in an aggregate principal amount of up to $3,000,000 (“Convertible Debentures”). Simultaneously with the
execution of this Standby Commitment Term Sheet, the Purchasers will provide reasonable assurance of financial ability to comply with the obligations hereunder.
			
	Issuer:	  	Authentidate	  	
				
	Purchasers:	  	Purchasers	  	Commitment	  	
	  	VER 83 LLC	  	$3,000,000	  	
		
	Total Commitment Amount:	  	$3,000,000 (the “Total Commitment Amount”), subject to downward adjustment, as provided below. Each Purchasers maximum commitment is set forth above.

		
	Commitment Fee Warrants:	  	Upon the execution of Definitive Agreements, Authentidate shall contemporaneously issue to the Purchasers 400,000 common stock purchase warrants (the
“Commitment Warrants”), pro rata based on each Purchasers Maximum Commitment. The exercise price of the Commitment Warrants shall be equal to the initial Conversion Rate of the Convertible Debentures. The Commitment Warrants shall
be exercisable for a period of five years from the date of issuance and shall be in a form mutually acceptable to Authentidate and the Purchasers and will have appropriate and customary terms and provisions, including customary anti-dilution
protection in the event of stock splits, stock dividends, recapitalizations, consolidations, merger or similar events. The Holders will be entitled to exercise the Commitment Warrants through cashless exercise provisions in the event the Common
Stock to be issued

			
		  	upon the exercise of the Commitment Warrants is not registered pursuant to an effective registration statement filed with the Securities and Exchange Commission. The Commitment
Warrants shall be registered in the name of Duke 87, LLC.
		
	Drawdown Warrants:	  	Upon the closing of a Drawdown, Authentidate shall contemporaneously issue to each Purchaser 13,333 common stock purchase warrants (the “Drawdown Warrants”) for
each $100,000 principal amount of Convertible Debentures purchased by such Purchaser. The exercise price of the Drawdown Warrants shall be equal to the Conversion Rate of the Convertible Debentures. The Drawdown Warrants shall be exercisable for a
period of five years from the date of issuance and shall be in a form mutually acceptable to Authentidate and the Purchasers and will have appropriate and customary terms and provisions, including customary anti-dilution protection in the event of
stock splits, stock dividends, recapitalizations, consolidations, merger or similar events. The Holders will be entitled to exercise the Drawdown Warrants through cashless exercise provisions in the event the common stock to be issued upon the
exercise of the Drawdown Warrants is not registered pursuant to an effective registration statement filed with the Securities and Exchange Commission. The Drawdown Warrants shall be registered in the name of Duke 87, LLC.
		
	Term of Commitment:	  	The 12-month period commencing on the Effective Date (defined below) (the “Commitment Term”), subject to early termination by Authentidate, as provided below.

		
	Drawdowns on Commitment:	  	From time to time during the Commitment Term, upon no less than 30 days’ written notice by Authentidate to the Purchasers, the Purchasers shall purchase Convertible
Debentures in the aggregate amount specified in such written notice (the “Drawdown”). The Purchasers shall purchase the Convertible Debentures pro rata based on each Purchasers Maximum Commitment and the amount of each Drawdown. The
closings of such purchases shall occur on or prior to the 30th day following the dates of such written notices or on such other dates as Authentidate and the Purchasers may agree from time to time.
		
	Use of Proceeds:	  	No restrictions.
		
	Early Termination of Commitment:	  	At any time during the Commitment Term, Authentidate may terminate the Purchasers’ obligation to purchase Convertible Debentures by providing the Purchaser with a written
notice of its intention to terminate such obligation and redeeming the Convertible Debentures then outstanding.
		
	Maturity Date of Convertible Debentures:	  	Eighteen months after the date of issuance (the “Maturity Date”), subject to early redemption, as provided below.
		
	Interest on Convertible Debentures:	  	10% per annum, accruing monthly and payable in cash, or at the option of Authentidate, in shares of Common Stock (“Dividend Shares”), within the 15-day period following
each calendar quarter,

  

 2 

			
		  	on the Maturity Date and on the date of redemption (if any). The Dividend Shares shall be valued at the most recent closing bid price of Authentidate’s common stock reported
on the Nasdaq Capital Market prior to the date of payment of the dividend.
		
	Conversion Feature of Convertible Debentures:	  	At any time and from time to time prior to the Maturity Date and prior to redemption (if any), upon no less than 15 days’ written notice by the Purchaser to Authentidate,
all or a portion of the principal amount of outstanding Convertible Debentures may be converted into shares of Authentidate’s common stock (“Conversion Shares”) at a conversion rate equal to $1.20 (the “Conversion
Rate”). In calculating the number of Conversion Shares to be issued to the Purchasers, such number shall be rounded up or down to the nearest whole number. Authentidate shall not issue any fractional Conversion Shares under any
circumstances, nor shall Authentidate be required to pay any cash amounts in respect of the value of any fractional Conversion Shares that may have been issuable in the absence of the aforementioned prohibition.
		
	Redemption Feature of Convertible Debentures:	  	At any time and from time to time prior to the Maturity Date, upon no less than 30 days’ written notice by Authentidate to the Purchaser (the “Redemption
Notice”), all or a portion of the then outstanding Convertible Debentures may be redeemed by payment of the principal amount thereof and the accrued and unpaid interest thereon at the end of such 30-day notice period. At any time during
such 30-day notice period, a Purchaser may exercise the conversion feature of the Convertible Debentures that are the subject of the Redemption Notice, by providing written notice to Authentidate of his intention to exercise such conversion feature.
The Conversion Shares underlying such Convertible Debentures shall be issued by Authentidate on or prior to the 15th
 day following the date of the Purchaser’s notice of his intention to exercise such conversion feature.
		
	Anti-dilution:	  	If, while any Convertible Debentures are outstanding, Authentidate should effect a split or a consolidation of its common stock, or should pay to its stockholders a dividend or
distribution in additional shares of its common stock without payment of any consideration therefor, then the Conversion Rate shall be increased or decreased appropriately such that the number of Conversion Shares issuable upon conversion of
Convertible Debentures shall be increased or decreased in proportion to the increase or decrease in the aggregate number of issued and outstanding shares of Authentidate’s common stock as a result of such split, consolidation, dividend or
distribution.
		
	Security:	  	First priority lien on the property and building located at 2165 Technology Drive, Schenectady, New York 12308 (the “Property”) and all of the outstanding shares
of capital stock of Authentidate’s subsidiary, Authentidate AG, and a general lien on all of the assets of Authentidate.
		
	Priority	  	The Convertible Debentures will be senior secured obligations of Authentidate. No other indebtedness, whether secured or

  

 3 

			
		  	unsecured, may be issued by Authentidate while the Convertible Debentures are outstanding, unless such indebtedness is specifically subordinated in all respects to the
Convertible Debentures.
		
	5% Limitation	  	No holder of a Commitment Warrant or a Drawdown Warrant may exercise such warrant, and no holder of a Convertible Debenture may convert such Convertible Debenture, if the shares
received upon such exercise or conversion, when added to shares of Authentidate’s common stock beneficially owned by such holder at the time of, or any time within sixty days prior to, the date of such exercise or conversion, would, in the
aggregate, be equal to or exceed 5% of the outstanding shares of Authentidate as determined in accordance with Regulation 13D, promulgated under the Securities Exchange Act of 1934, as amended.
		
	Third Party Financing:	  	If, while there are any Convertible Debentures outstanding, Authentidate 1) closes a financing with a third party, whether by way of debt, equity or otherwise, 2) sells the
Property, or 3) sells all or a portion of the shares of Authentidate AG, (collectively a “Financing”) then, in accordance with the provisions appearing beside the heading “Redemption Feature of Convertible Debentures”
above, Authentidate shall deliver a written notice to the Purchaser of Authentidate’s intention to redeem the maximum number of the then outstanding Convertible Debentures of which the net proceeds to Authentidate of such Financing (the
“Net Proceeds”) would be sufficient to repay the aggregate principal amount and accrued and unpaid interest thereon. Unless a Purchaser elects to exercise the conversion feature of such Convertible Debentures in accordance with the
provisions appearing beside the heading “Redemption Feature of Convertible Debentures” above, Authentidate shall use the Net Proceeds to redeem such Convertible Debentures in accordance with such provisions. In addition, to the extent that
the Net Proceeds are more than sufficient to redeem all of the then outstanding Convertible Debentures (and the Financing occurs during the Commitment Term), the then-undrawn portion of the Total Commitment Amount shall be reduced automatically upon
the closing of a Financing by the lesser of: (i) the then-undrawn portion of the Total Commitment Amount; or (ii) an amount equivalent to the difference between (x) the total amount of the Net Proceeds and (y) the amount required to redeem the
Convertible Debentures subject to the above-mentioned redemption notice. If a Financing occurs during the Commitment Term while there are no Convertible Debentures outstanding, the Total Commitment Amount shall be reduced automatically upon the
closing of the Financing by the lesser of: (i) the Total Commitment Amount; or (ii) the Net Proceeds.
		
	Covenant to Negotiate and Enter into a Definitive Agreement:	  	Authentidate and the Purchasers will negotiate in good faith, and enter into, as soon as practicable, definitive agreements with respect to the proposed transactions contemplated
in this Standby Commitment Term Sheet (the “Definitive Agreement”). The provisions of the Definitive Agreement will be consistent with the provisions of this Standby Commitment Term Sheet and will

  

 4 

			
		  	contain other terms and conditions customary and reasonable for transactions of the nature contemplated in this Standby Commitment Term Sheet, including, without limitation, the
form of the Convertible Debentures and Warrants.
		
	Conditions Precedent to Drawdowns on Commitment:	  	 •     Execution and delivery of the Definitive Agreement and
all ancillary agreements contemplated thereby
  
 •     Execution and delivery of Convertible Debentures and Warrants
  
 •     Absence of default under the provisions of this Standby Commitment Term Sheet or
any relevant definitive agreement
  
 •     Receipt of all necessary regulatory consents or approvals

		
	Events of Default:	  	The Convertible Debentures will contain events of default customarily found in agreements for similar financings and other events of default deemed by Purchasers to be
appropriate to the specific transaction, including, without limitation, failure to make payments when due; noncompliance with covenants; breaches of representations and warranties; payment default with respect to any other material indebtedness;
failure to satisfy or stay executions of judgments in excess of specified amounts; the occurrence of certain materially adverse events; and change of ownership or control.
		
	Syndication and Assignment:	  	Subject to applicable securities laws, the Convertible Debentures may be syndicated, sold and assigned by the Purchaser to one or more third parties, and rights of the Purchaser
under this Standby Commitment, the Definitive Agreement, the Convertible Debentures and any other relevant definitive agreement may be assigned by the Purchaser to such third party or parties. Authentidate shall co-operate with the Purchaser in
connection with any such syndication, sale or assignment and, among other things, shall execute and deliver documents reasonably necessary to facilitate the same.
		
	Independent Advice:	  	Each Purchaser represents and warrants to Authentidate that he has read this Standby Commitment Term Sheet and understands his obligations under it. Each Purchaser further
represents and warrants to Authentidate that he has had an adequate opportunity to seek and obtain independent legal and financial advice in connection with this Standby Commitment Term Sheet and such other professional advice that he considered
necessary or appropriate.
		
	Binding Nature:	  	This Standby Commitment Term Sheet is legally binding. Each of Authentidate and the Purchasers, on its and their own behalf, respectively, represents and warrants that this
Standby Commitment Term Sheet is a valid and legally binding obligation of it or him, respectively, enforceable in accordance with the terms of this Standby Commitment Term Sheet.
		
	Governing Law:	  	Delaware

  

 5 

 IN WITNESS WHEREOF, the parties have executed and delivered this Standby Commitment Term Sheet as
of the 22 day of September, 2009 (the “Effective Date”). 
  

							
	Acceptance	 	Authentidate and Purchaser hereby agree that the terms set forth above are acceptable to each of them.
			
		 	AUTHENTIDATE HOLDING CORP.	  	
				
		 	By:	  	 O’Connell Benjamin
	  	
		 		  	Name:	  	
		 		  	Title:	  	
			
		 	VER 83 LLC	  	
				
		 	By:	  	 /s/ Douglas Luce
	  	
		 		  	Name: Douglas Luce	  	
		 		  	Title: Manager	  	

  

 6Lease Termination and Warrant Purchase Agreement

 Exhibit 10.1 
 LEASE TERMINATION AND WARRANT PURCHASE AGREEMENT 
 THIS LEASE TERMINATION AND WARRANT PURCHASE AGREEMENT (this “Agreement”) is entered into as of this 18th day of September, 2009, by and between BMR-201 INDUSTRIAL ROAD LLC, a Delaware limited liability company
(“Landlord”), BIOMED REALTY, L.P., a Maryland limited partnership (“BioMed”), and ARCA BIOPHARMA, INC., a Delaware corporation (f.k.a., Nuvelo, Inc., “Tenant”). 
 RECITALS 
 A. WHEREAS, Landlord and Tenant entered into that certain that certain Lease dated as of January 11, 2005, as amended by that certain First Amendment to Lease dated as of May 10, 2005 and that certain Second Amendment to Lease
dated as of February 23, 2006 (collectively, and as the same may have been further amended, supplemented or otherwise modified from time to time, the “Lease”), whereby Tenant leases certain premises (the
“Premises”) from Landlord at 201 Industrial Road in San Carlos, California; 
 B. WHEREAS, Tenant, as
sublandlord, and Bernard Hodes Group, Inc., a Delaware corporation (“BHG”), as subtenant, entered into that certain Sublease dated as of January 17, 2008 (the “BHG Sublease”), for a portion of the Premises
(such portion, the “BHG Premises”), and Landlord consented to the BHG Sublease pursuant to that certain Consent to Sublease dated as of January 17, 2008 (the “BHG Consent”), by and among Landlord, Tenant and
BHG; 
 C. WHEREAS, Landlord, Tenant and BHG intend to modify the BHG Sublease and BHG Consent by entering into that certain
First Amendment to Sublease of even date herewith (the “Sublease Amendment”); and 
 D. WHEREAS, Landlord and
Tenant desire to terminate the Lease and, in connection therewith, Tenant shall issue to BioMed and BioMed shall purchase a warrant (the “Warrant”) to purchase shares of common stock of Tenant in accordance with the following
provisions. 
 AGREEMENT 
 NOW, THEREFORE, the parties hereto, in consideration of the mutual promises, representations, warranties and covenants contained herein and for other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows: 
 1. Termination.
Subject to the satisfaction of all of the terms conditions herein, Landlord and Tenant hereby terminate the Lease as of September 18, 2009 (the “Termination Date”). As of the Termination Date, the Lease shall be fully and
finally surrendered and terminated and shall no longer be of any force or effect, except for those provisions that, by their express terms, survive the expiration or earlier termination thereof. 

 2. Termination Consideration. Landlord and Tenant acknowledge that Tenant’s
Termination Option (as set forth in Section 4.6 of the Lease) is subject to Tenant’s satisfaction of certain conditions, including without limitation Tenant’s payment of any unamortized tenant improvements and leasing
commissions. Landlord and Tenant further acknowledge that the early termination of the Lease will result in certain losses and liabilities for Landlord (including, without limitation, loss of income; negative impact on Landlord’s ability to
sell, finance or refinance the Property; and increased costs associated with securing a replacement tenant(s)). Accordingly, the following (“Termination Consideration”) shall be full, fair and reasonable consideration in exchange
for Landlord’s agreement to terminate the Lease prior to its natural expiration: 
 a. Termination Payment. Within
one (1) business day after the mutual execution and delivery of this Agreement, Tenant shall pay Landlord immediately available funds that total Three Million Four Hundred Thirty-One Thousand One Hundred Eighty-One and 23/100s Dollars
($3,431,181.23); 
 b. Security Deposit. Landlord and Tenant acknowledge that Landlord holds cash in the amount of Four
Hundred Eighty-Nine Thousand Six Hundred Twenty-Three Dollars ($489,623) (“Security Deposit”). Notwithstanding anything to the contrary in the Lease, Landlord is immediately entitled to the entire amount of the Security Deposit
without the need for notice to Tenant or affording Tenant, or any other party, an opportunity to cure. In addition, Landlord shall remain entitled to draw on the Security Deposit for any other purpose set forth in the Lease or this Agreement;

 c. Warrant. Tenant shall, within thirty (30) days after full execution and delivery of this Agreement (the
“Warrant Issuance Date”), deliver to BioMed, and BioMed shall purchase from Tenant, the Warrant, in the form attached hereto as Exhibit A for a purchase price of Ten Dollars ($10). BioMed hereby acknowledges, agrees to
and affirms that (i) all representations and warranties set forth in Section 4 of the Warrant are true and correct in all respects as of the date hereof and shall be true and correct in all respects as of the Warrant Issuance Date, and
(ii) Tenant shall have no obligation to execute and deliver the Warrant unless all representations and warranties set forth in Section 4 of the Warrant are true and correct in all respects as of the date hereof and as of the Warrant
Issuance Date. 
 d. Assignment of BHG Sublease. Effective as of the Termination Date, Tenant hereby assigns to Landlord
all of its right, title and interest as “Sublandlord” under the BHG Sublease, and commencing as of the Termination Date subject to the Sublease Amendment, Landlord hereby accepts such assignment and assumes the performance of all
obligations of Tenant as “Sublandlord” under the BHG Sublease, as such lease may be further modified by Landlord and BHG. 
 3. Release of Liability. 
 a. By Tenant. Tenant hereby fully and unconditionally releases, cancels,
annuls, rescinds, discharges, disclaims, waives and releases any and all rights and benefits it may have under the Lease or BHG Consent, any right to inspect Landlord’s records for Taxes and Operating Costs, any claims of credit for overpaid
Rent (including Operating Costs) or any other

  

 2 

 
amounts paid to Landlord, and the right to collect any amounts under the BHG Sublease arising from and after the Termination Date. Tenant acknowledges that as of the Termination Date, Landlord
shall have the right to collect any amounts due to Tenant under the BHG Sublease as if Landlord was “Sublandlord” (as defined in the BHG Sublease), without obligation or liability to Tenant and without obligation or liability to BHG for
prepaid rent or security deposit under the BHG Sublease. 
 b. By Landlord. Subject to Tenant’s compliance with
those terms that survive the expiration or termination of the Lease, Landlord hereby fully and unconditionally releases, cancels, annuls, rescinds, discharges, disclaims, waives and releases any and all rights and benefits it may have under the
Lease or BHG Consent and any right to claim any future payment for adjustments to Monthly Rent and Operating Costs. Landlord acknowledges that as of the Termination Date, subject to the Sublease Amendment, Landlord shall have the rights, and
obligations to perform, of Tenant under the BHG Sublease, as such lease may be further modified by Landlord and BHG. 
 4.
Indemnification. Tenant shall protect, defend, indemnify, release, save and hold Landlord and each of Landlord’s officers, directors, successors, affiliates, employees, agents, consultants and lenders (each, an “Indemnified
Party”) harmless from and against any and all Losses (as defined below) imposed upon or incurred by or asserted against such Indemnified Party and directly or indirectly arising out of or in any way relating to (a) the inaccuracy of
any representation of Tenant herein, or (b) Tenant’s failure to perform or comply with any obligations or covenants (i) prior to the Termination Date (A) of Tenant under the Lease, (B) of “Sublandlord” under the
BHG Sublease or (C) otherwise as set forth in the Lease, BHG Sublease or the BHG Consent, including, without limitation, any failure to refund pre-paid rent or security deposit to BHG, or (ii) after the Termination Date of Tenant pursuant
to this Agreement (including, without limitation, with respect to provisions of the Lease that expressly survive the expiration or earlier termination thereof). As used herein, the term “Losses” includes any and all claims, suits,
liabilities, actions, proceedings, obligations, debts, damages, losses, costs, expenses, diminutions in value, fines, penalties, charges, liens, fees, expenses, judgments, awards, amounts paid in settlement, punitive damages and foreseeable and
unforeseeable consequential damages of whatever kind or nature (including, without limitation, attorneys’ fees and other costs of defense). 
 5. Quitclaim. To the extent, if any, that the Lease gives Tenant any right, title or interest in or to the Premises, Tenant does, effective as of the Termination Date, hereby remise, release and
quitclaim to Landlord such right, title or interest in or to the Premises and shall execute and deliver to Landlord any documentation reasonably requested by Landlord to effect or document such remise, release and quitclaim. 
 6. Condition of Premises. On or prior to the Termination Date, Tenant shall surrender the Premises to Landlord in the condition
required under the Lease. 
 7. FF&E. Tenant hereby conveys all right, title and interest to all furniture, fixtures
and equipment (“FF&E”) located in the Premises as of the date hereof, and represents to Landlord that none of the FF&E has been or will be damaged, modified or removed from the

  

 3 

 
Premises. If requested by Landlord, Tenant shall execute and deliver to Landlord a separate bill of sale covering the FF&E in form and substance reasonably acceptable to Landlord and Tenant.

 8. Representations of Parties. Each of Landlord and Tenant represents that it has not made any assignment, sublease
(other than the BHG Sublease), transfer, conveyance or other disposition of the Lease or any interest therein, nor made or entered into any agreement that would result in any mechanic’s lien or other claim, demand, obligation, liability, action
or cause of action arising from or with respect to the Lease or the Premises. Tenant hereby represents and warrants to Landlord that, with respect to the BHG Sublease, (a) BHG has not prepaid more than one (1) month’s rent (i.e.,
beyond rent paid for September, 2009), (b) Tenant will promptly return to BHG any security deposit or other security in connection with the BHG Sublease, and (c) to Tenant’s knowledge, there are no defaults, or conditions existing
that with the passage of time may become a default, whether on behalf of Landlord, Tenant, or BHG under the BHG Sublease or BHG Consent. 
 9. Miscellaneous. 
 a. Voluntary Agreement. The parties have read
this Agreement and the mutual releases contained in it, and have freely and voluntarily entered into this Agreement. 
 b.
Attorneys’ Fees. If any party commences an action against the other party arising out of or in connection with this Agreement (other than the Warrant), the prevailing party shall be entitled to recover from the losing party reasonable
attorneys’ fees and costs of suit. 
 c. Successors. This Agreement shall be binding on and inure to the benefit of
the parties and their successors and assigns. 
 d. Counterparts. This Agreement may be executed in one or more
counterparts that, when taken together, shall constitute one original. 
 e. Defined Terms. Capitalized terms not
otherwise defined herein shall have the meanings given them in the Lease. 
 f. Amendment. This Agreement (but excluding
the Warrant) may only be amended or modified by written agreement between the parties. 
 g. Applicable Law. This
Agreement (but excluding the Warrant) shall be governed by and construed in accordance with the laws of the State, or Commonwealth, in which the Premises are located applicable to contracts made and to be performed State, or Commonwealth, in which
the Premises are located, without regard to conflict of law principles. 
 h. Conflict. In the event of any conflict or
discrepancy between the provisions of this Agreement (but excluding the Warrant) and the provisions of the Lease, BHG Sublease or Sublease Consent, or any other document between the parties (but excluding the Warrant), the provisions of this
Agreement shall control. 
 i. Entire Agreement. This Agreement, the Sublease Amendment and the Warrant set forth the
entire understanding of the parties relating to the transaction contemplated

  

 4 

 
hereby, and supersede all prior understandings, whether written or oral. There are no obligations, commitments, representations or warranties relating to them except those expressly set forth in
this Agreement, the Sublease Amendment and the Warrant. 
 j. Binding Agreement. This Agreement shall be binding upon and
inure to the benefit of the parties and their successors, assigns, parents, subsidiaries, divisions and affiliates. 
 [REMAINDER
OF THIS PAGE INTENTIONALLY LEFT BLANK] 
  

 5 

 IN WITNESS WHEREOF, the parties have executed this Lease Termination Agreement as of the day
hereinabove first written. 
  

			
	LANDLORD:
	
	 BMR-201 INDUSTRIAL ROAD LLC,
 a Delaware limited liability company

		
	By:	 	 /s/    Kevin M. Simonsen

	Name:	 	Kevin M. Simonsen
	Its:	 	VP, Real Estate Counsel
	
	BIOMED:
	
	 BIOMED REALTY, L.P.,
 a Maryland limited partnership

		
	By:	 	 /s/    Kevin M. Simonsen

	Name:	 	Kevin M. Simonsen
	Its:	 	VP, Real Estate Counsel
	
	TENANT:
	
	 ARCA BIOPHARMA, INC.,
 a Delaware corporation

		
	By:	 	 /s/    Christopher D. Ozeroff

	Name:	 	Christopher D. Ozeroff
	Its:	 	EVP of Business Development,
		 	General Counsel and Secretary

 EXHIBIT A 
 WARRANT 

 THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES
ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAW, AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF OR EXERCISED UNLESS (I) A REGISTRATION STATEMENT
REGISTERING SUCH SECURITIES UNDER THE SECURITIES ACT AND APPLICABLE STATE SECURITIES LAWS SHALL HAVE BECOME EFFECTIVE, OR (II) THE CORPORATION HAS RECEIVED AN OPINION OF COUNSEL SATISFACTORY TO IT THAT SUCH TRANSFER MAY LAWFULLY BE MADE WITHOUT
REGISTRATION UNDER THE SECURITIES ACT OR QUALIFICATION UNDER APPLICABLE STATE SECURITIES LAWS, OR (III) SUCH SECURITIES ARE SOLD PURSUANT TO RULE 144. 
 AN INVESTMENT IN THESE SECURITIES INVOLVES A HIGH DEGREE OF RISK. HOLDERS MUST RELY ON THEIR OWN ANALYSIS OF THE INVESTMENT AND ASSESSMENT OF THE RISKS INVOLVED. 
 ARCA BIOPHARMA, INC. 
 WARRANT TO PURCHASE COMMON
STOCK 
  

			
	 No. CW – 
	 	October 18, 2009

 This certifies that, for value received, BioMed Realty, L.P., with its principal
office at 17190 Bernardo Center Drive, San Diego, California 92128, or its permitted assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (as defined below) from ARCA biopharma, Inc., a Delaware
corporation, with its principal office at 8001 Arista Place, Suite 200, Broomfield, Colorado 80021 (the “Corporation”), up to a number of Exercise Shares (as defined below), upon the terms and subject to the adjustments as provided
herein. 
 This Warrant is being issued pursuant to the terms of the Lease Termination and Warrant Purchase Agreement, dated
September 18, 2009 (the “Lease Termination and Warrant Purchase Agreement”) by and among the Corporation, BMR-201 Industrial Road LLC, a Delaware limited liability company, and the Holder. Capitalized terms used herein but not
otherwise defined shall have the meanings given to them in the Lease Termination and Warrant Purchase Agreement. 
 1.
Definitions. As used herein, the following terms shall have the following respective meanings: 
 (a)
“Exercise Period” shall mean the time period commencing with the date of this Warrant and ending on the earlier of (i) the date that is seven (7) years from date of this Warrant, or (ii) the commencement of any
liquidation, bankruptcy, insolvency, dissolution or winding-up (or the occurrence of any analogous proceeding) of the Corporation. 
 (b) “Exercise Price” shall mean $3.82 per share subject to adjustment pursuant to the terms herein, including Section 5 below. 
 (c) “Exercise Shares” shall mean 130,890 shares of common stock of the Corporation (the “Common Stock”) subject to adjustment pursuant to the terms herein,
including Section 5 below. 

 2. EXERCISE OF WARRANT.

 2.1 IN GENERAL. The rights represented by this Warrant may be exercised in whole or in
part at any time during the Exercise Period, by delivery of the following to the Corporation at its address set forth above (or at such other address as it may designate by notice in writing to the Holder): 
 E. an executed Notice of Exercise in the form attached hereto; 
 F. payment of the Exercise Price either (i) in cash or by check, or (ii) pursuant to Section 2.2 below; and 
 G. this Warrant. 
 Upon the exercise of the rights represented by this Warrant, a
certificate or certificates for the Exercise Shares so purchased, registered in the name of the Holder or persons affiliated with the Holder, if the Holder so designates, shall be issued and delivered to the Holder as soon as practicable after the
rights represented by this Warrant shall have been so exercised. 
 The person in whose name any certificate or certificates for
Exercise Shares are to be issued upon exercise of this Warrant shall be deemed to have become the holder of record of such shares on the date on which this Warrant was surrendered and payment of the Exercise Price was made, irrespective of the date
of delivery of such certificate or certificates, except that, if the date of such surrender and payment is a date when the stock transfer books of the Corporation are closed, such person shall be deemed to have become the holder of such shares at
the close of business on the next succeeding date on which the stock transfer books are open. In the event that this Warrant is exercised in respect of fewer than all of the Exercise Shares issuable on such exercise at any time prior to the date of
expiration of this Warrant, a new certificate evidencing the remaining Warrant will be issued, in a form substantially identical hereto, in the name of the Holder, and delivered to the Holder or to another person that the Holder has designated for
delivery as soon as practicable. 
 This Warrant shall be null and void, and the rights represented hereby shall automatically
expire immediately upon the expiration of the Exercise Period. 
 2.2 Net Exercise. Notwithstanding any provisions herein
to the contrary, if the fair market value of one share of the Corporation’s Common Stock is greater than the Exercise Price (at the date of calculation as set forth below), in lieu of exercising this Warrant by payment of cash, the Holder may
elect to receive shares equal to the value (as determined below) of this Warrant (or the portion thereof being canceled) by surrender of this Warrant at the principal office of the Corporation together with the properly endorsed Notice of Exercise,
in which event the Corporation shall issue to the Holder a number of shares of Common Stock computed using the following formula: 

 X = Y (A-B) 
 A 
 Where: 
  

	 	X =	the number of shares of Common Stock to be issued to the Holder 

  

	 	Y =	the number of shares of Common Stock purchasable under the Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled
(at the date of such calculation) 

  

	 	A =	the fair market value of one share of the Corporation’s Common Stock (at the date of such calculation) 

  

	 	B =	Exercise Price (as adjusted to the date of such calculation) 

 For purposes of the above calculation, for so long as the Corporation’s Common Stock is traded in a public market, the fair market value of each share of Common Stock shall be the closing price of a
share of Common Stock for the business day immediately before the day the Holder delivers its Notice of Exercise to the Corporation. If the Corporation’s Common Stock is not traded in a public market, the fair market value of one share of
Common Stock shall be determined by the Corporation’s Board of Directors in good faith. 
 3.
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE CORPORATION. The Corporation hereby represents and covenants to the Holder as of the date
hereof, and with respect to Sections 3.3 and 3.5 for so long as the Holder holds the Warrant or any Exercise Shares, as follows: 
 3.1 Covenants as to Exercise Shares. The Corporation covenants and agrees that all Exercise Shares that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding,
fully paid and nonassessable, and free from all taxes, liens and charges with respect to the issuance thereof. The Corporation further covenants and agrees that the Corporation shall at all times during the Exercise Period have authorized and
reserved, free from preemptive rights, a sufficient number of shares of its Common Stock to provide for the exercise of the rights represented by this Warrant. 
 3.2 Notices of Record Date. In the event of any taking by the Corporation of a record of the holders of any class of securities for the purpose of determining the holders thereof who are entitled
to receive any dividend (other than a cash dividend which is the same as cash dividends paid in previous quarters) or other distribution, the Corporation shall mail to the Holder, at least ten (10) days prior to the date specified herein, a
notice specifying the date on which any such record is to be taken for the purpose of such dividend or distribution. 
 3.3
Health Care / Lodging Facilities. The Corporation does not operate or manage any health care facilities (including a congregate care facility or assisted living facility) or lodging facilities or provide any person, under a franchise, license or
otherwise, rights to any brand name under which any lodging facility or health care facility is operated. 
 3.4 Percentage
of Outstanding Stock. As of the date hereof, the Exercise Shares for which this Warrant may be exercised in full represent less than five percent (5.0%) of the voting interest and less than five percent (5.0%) of the value of the
outstanding stock of the Corporation. 

 3.5 Notification. Upon the written request of the Holder, the Corporation shall,
within five (5) days confirm in writing to the Holder whether the Exercise Shares for which this Warrant may be exercised in full constitute greater than five percent (5.0%) of the voting interest and/or greater than five percent
(5.0%) of the value of the outstanding stock of the Corporation. 
 4. REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE OF HOLDER. 
 4.1 Acquisition of Warrant for Personal Account. The Holder represents and warrants that it is acquiring the Warrant solely for his, her or its account for investment and not with a view to or for
sale or distribution of said Warrant or any part thereof, other than potential transfers between affiliates. The Holder also represents that the entire legal and beneficial interests of the Warrant and Exercise Shares the Holder is acquiring is
being acquired for, and will be held for, his, her or its account only. 
 4.2 Securities Are Not Registered. 

(a) The Holder understands that the Warrant and the Exercise Shares have not been registered under the Securities Act of 1933, as
amended (the “Act”) on the basis that no distribution or public offering of the stock of the Corporation is to be effected. The Holder realizes that the basis for the exemption may not be present if, notwithstanding his, her or its
representations, the Holder has a present intention of acquiring the securities for a fixed or determinable period in the future, selling (in connection with a distribution or otherwise), granting any participation in, or otherwise distributing the
securities. The Holder has no such present intention. 
 (b) The Holder is an “accredited investor” within the
meaning of Regulation D promulgated under the Act. 
 (c) The Holder recognizes that the Warrant and the Exercise Shares
must be held indefinitely unless they are subsequently registered under the Act or an exemption from such registration is available. 
 (d) The Holder is aware of Rule 144 adopted under the Act and the conditions of permitted sales in reliance thereof. 
 4.3 Disposition of Warrant and Exercise Shares. The Holder further agrees not to make any disposition of all or any part of the Warrant or Exercise Shares in any event unless and until: 
 (a) The Corporation shall have received a letter secured by the Holder from the Securities and Exchange Commission stating that no
action will be recommended to the Commission with respect to the proposed disposition; or 
 (b) There is then in effect
a registration statement under the Act covering such proposed disposition and such disposition is made in accordance with said registration statement; or 
 (c) The Holder shall have notified the Corporation of the proposed disposition and shall have furnished the Corporation with a statement of the circumstances surrounding the proposed disposition;
provided, however, that such statement will not be required if the disposition is permitted under Rule 144 of the Act, except in unusual circumstances. 

 5. ADJUSTMENT OF EXERCISE
PRICE AND EXERCISE SHARES; EFFECT OF ORGANIC CHANGES; CUTBACKS 
 5.1 Adjustment of Exercise Price and/or Exercise Shares. In the event of changes in the outstanding capital stock of the Corporation
by reason of stock dividends, splits, recapitalizations, reclassifications, combinations or exchanges of shares, separations, reorganizations, liquidations, or the like, the number and class of shares available under the Warrant in the aggregate and
the Exercise Price shall be correspondingly adjusted to give the Holder of the Warrant, on exercise for the same aggregate Exercise Price, the total number, class, and kind of shares as the Holder would have owned had the Warrant been exercised
immediately prior to the event and had the Holder continued to hold such shares until after the event requiring adjustment. The Corporation will provide prompt written notice to the Holder describing the change and the corresponding adjustment of
the Exercise Price or number of Exercise Shares subject to this Warrant made pursuant to this section. 
 5.2 Reorganization,
Reclassification, Consolidation, Merger or Sale. If any recapitalization, reclassification or reorganization of the capital stock of the Corporation, or any consolidation or merger of the Corporation with another corporation, or the sale of all
or substantially all of its assets or other transaction shall be effected in such a way that holders of the Corporation’s Common Stock shall be entitled to receive stock, securities, or other assets or property, including, without limitation,
upon conversion of such Common Stock (an “Organic Change”), then, as a condition of such Organic Change, lawful and adequate provisions shall be made by the Corporation whereby the Holder hereof shall thereafter have the right to
purchase and receive (in lieu of the shares of the Common Stock of the Corporation immediately theretofore purchasable and receivable upon the exercise of the rights represented hereby) such shares of stock, securities or other assets or
property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal to the number of shares of such stock immediately theretofore purchasable and receivable upon the exercise of the
rights represented hereby. In the event of any Organic Change, appropriate provision shall be made by the Corporation with respect to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without
limitation, provisions for adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the exercise of this Warrant) shall thereafter be applicable, in relation to any shares of stock, securities or assets
thereafter deliverable upon the exercise hereof and following such Organic Change the Corporation or its successor shall promptly issue to Holder an amendment to this Warrant reflecting such adjustments. 
 5.3 Certain Events. If any change in the outstanding Common Stock of the Corporation or any other event occurs as to which the other
provisions of this Section 5 are not strictly applicable or if strictly applicable would not fairly protect the purchase rights of the Holder of the Warrant in accordance with such provisions, then the Board of Directors of the Corporation
shall make, in good faith, an adjustment in the number and class of shares available under the Warrant, the Exercise Price or the application of such provisions, so as to protect such purchase rights as aforesaid. The adjustment shall be such as to
give the Holder of the Warrant upon exercise for the same aggregate Exercise Price the total number, class and kind of shares as he would have owned had the Warrant been exercised prior to the event and had he continued to hold such shares until
after the event requiring adjustment. The Corporation will provide prompt written notice to the Holder describing the change and the corresponding adjustment of the Exercise Price or number of Exercise Shares subject to this Warrant made pursuant to
this section. 

 6. FRACTIONAL SHARES. No fractional
shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Exercise Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the
exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Corporation shall, in lieu of issuance of any fractional share, pay the Holder otherwise
entitled to such fraction a sum in cash equal to the product resulting from multiplying the then current fair market value of an Exercise Share by such fraction. 
 7. NO STOCKHOLDER RIGHTS. This Warrant in and of itself shall not entitle the Holder to any voting rights or other rights as a
stockholder of the Corporation. 
 8. TRANSFER OF WARRANT. Subject to
applicable laws and any restrictions on transfer set forth in this Warrant, this Warrant and all rights hereunder are transferable, by the Holder in person or by duly authorized attorney, upon delivery of this Warrant and the form of assignment
attached hereto to any transferee designated by Holder. 
 9. LOST, STOLEN,
MUTILATED OR DESTROYED WARRANT. The Corporation covenants to the Holder that, upon receipt of evidence reasonably satisfactory to the Corporation of the loss, theft,
destruction or mutilation of this Warrant or any stock certificate and, in the case of any such loss, theft or destruction, upon receipt of an indemnity reasonably satisfactory to the Corporation, or in the case of any such mutilation, upon
surrender and cancellation of such Warrant or stock certificate, the Corporation will make and deliver a new Warrant or stock certificate, of like tenor, in lieu of the lost, stolen, destroyed or mutilated Warrant or stock certificate. 

10. NOTICES, ETC. Any notice required or permitted under this Warrant shall be given in writing and
shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed facsimile if sent during normal business hours of the recipient; if not, then on the next business day, (c) five
(5) business days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, specifying next day
delivery, with written verification of receipt. All communications shall be sent to (i) the Corporation at the address set forth above, Attention: Chief Executive Officer and General Counsel; or to (ii) the Holder at his, her or its
address set forth above, or at such other address as any such party may designate by ten (10) days advance written notice to the other parties hereto. 
 11. ACCEPTANCE. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein. 
 12. GOVERNING LAW. This Warrant and all rights, obligations and liabilities hereunder
shall be governed and construed under the laws of the State of Colorado in all respects as such laws are applied to agreements among Colorado residents entered into and performed entirely within Colorado, without giving effect to conflict of law
principles thereof. The Corporation and Holder agree that any action brought by any party under or in relation to this Warrant, including without limitation to interpret or enforce any provision of this Warrant, shall be brought in, and each agrees
to and does hereby submit to the jurisdiction and venue of, any state or federal court located in the County of Denver, Colorado. 
 [Signature Page Follows] 

 IN WITNESS WHEREOF, the
Corporation has caused this Warrant to be executed by its duly authorized officer as of                     . 
  

			
	ARCA BIOPHARMA, INC.
		
	By:	 	  

		
	Print Name:	 	  

		
	Title:	 	  

 NOTICE OF EXERCISE 
  

	TO:	ARCA biopharma, Inc. 

 8001 Arista Place, Suite 200 
 Broomfield, CO 80021 
 Attention: Chief Executive Officer and General Counsel 
 (1)     ̈    The undersigned hereby elects to purchase          shares of the
Common Stock of ARCA biopharma, Inc. (the “Corporation”) pursuant to the terms of the attached Warrant, and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. 
   ̈    The undersigned hereby elects to purchase
         shares of the Common Stock of the Corporation pursuant to the terms of the net exercise provisions set forth in Section 2.2 of the attached Warrant, and shall tender payment of all applicable
transfer taxes, if any. 
 (2) Please issue a certificate or certificates representing said shares of Common Stock in the name
of the undersigned or in such other name as is specified below: 
  

					
	  
	 		 	
	(Name)	 		 	
		 		 	
	  
	 		 	
	  
  
	 		 	
	(Address)	 		 	
		 		 	
	  
	 		 	  

	(Date)	 		 	(Signature)
		 		 	
		 		 	  

		 		 	(Print name)

 ASSIGNMENT FORM 
 (To assign the foregoing Warrant, execute this form and supply required 
 information. Do not use this form to purchase shares.) 
 FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to 
  

	
	 Name:                                      
                                         
                                         
                                         
                                         
   

	 (Please Print)

	
	 Address:
                                         
                                         
                                         
                                         
                                    

	 (Please Print)

	
	 Dated:
                    

	
	 Holder’s

	 Signature:
                                         
                                         
                                         
                                         
                                  

	
	 Holder’s

	 Address:
                                         
                                         
                                         
                                         
                                    

 NOTE: The signature to this Assignment Form must correspond with the name as it appears on the
face of the Warrant, without alteration or enlargement or any change whatsoever. Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Warrant.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00163-of-00352.parquet"}]]